Fraeyman Jessica, Foulon Veerle, Mehuys Els, Boussery Koen, Saevels Jan, De Vriese Carine, Dalleur Olivia, Housiaux Marie, Steurbaut Stephane, Naegels Marc, De Meyer Guido Ry, De Loof Hans, Van Hal Guido, Van den Broucke Stephan
Research Group Medical Sociology and Health Policy, University of Antwerp, Belgium.
Clinical Pharmacology and Pharmacotherapy, University of Leuven, Belgium.
Res Social Adm Pharm. 2017 Jan-Feb;13(1):98-108. doi: 10.1016/j.sapharm.2016.02.001. Epub 2016 Feb 12.
In October 2013, a New Medicines Service (NMS) was introduced in community pharmacies in Belgium to support asthma patients who are novice users of inhaler devices with corticosteroids. The protocol-based intervention used the Asthma Control Test (ACT) and the Medication Adherence Report Scale (MARS) to assess asthma control and medication adherence. The NMS is the first initiative that puts advanced pharmaceutical care into practice in Belgium. The present study evaluated the degree to which the NMS program is delivered as intended, drawing on the concept of implementation fidelity (IF).
The main dimensions of IF and potential moderating and facilitating factors for the implementation of NMS in community pharmacies were evaluated using telephone interviews with pharmacists (n = 497), semi-structured interviews with patients eligible for NMS (n = 30), focus groups among general practitioners (n = 72) and lung specialists (n = 5), and a work system analysis in community pharmacies (n = 19).
The uptake of NMS in Belgian community pharmacies remains low. In addition to practical barriers, pharmacists found it difficult to identify new asthmatic patients when they were not informed about the diagnosis. A lack of commitment from physicians, patients and pharmacists was noted in the early start-up phase of the program. Many pharmacists did not see how NMS differed from existing pharmaceutical care. Physicians considered this service as part of their own tasks and discouraged ACT for asthma follow-up in the community pharmacy.
The introduction of the NMS program was not sufficiently embedded in the Belgian health care organization, causing low uptake and resistance to its implementation by pharmacists, patients, and other health care professionals. To increase the uptake of this type of service and its possible extension to other patient groups, more collaboration among the different health care professionals during design and implementation is necessary, as well as systematic data collection to monitor the quality of the service, better training of pharmacists, and more information for patients and physicians.
2013年10月,比利时在社区药店推出了一项新药品服务(NMS),以支持首次使用含皮质类固醇吸入装置的哮喘患者。基于方案的干预措施使用哮喘控制测试(ACT)和药物依从性报告量表(MARS)来评估哮喘控制情况和药物依从性。NMS是比利时将高级药学服务付诸实践的首个举措。本研究利用实施保真度(IF)的概念,评估了NMS项目按预期实施的程度。
通过对药剂师进行电话访谈(n = 497)、对符合NMS条件的患者进行半结构化访谈(n = 30)、对全科医生(n = 72)和肺部专家(n = 5)进行焦点小组访谈以及对社区药店进行工作系统分析(n = 19),评估了IF的主要维度以及在社区药店实施NMS的潜在调节和促进因素。
比利时社区药店对NMS的接受程度仍然较低。除了实际障碍外,药剂师发现,在未被告知诊断信息时,很难识别出新的哮喘患者。在该项目启动初期,医生、患者和药剂师都缺乏积极性。许多药剂师看不出NMS与现有药学服务有何不同。医生认为这项服务是他们自身任务的一部分,并不鼓励在社区药店使用ACT进行哮喘随访。
NMS项目在比利时医疗保健组织中的引入不够深入,导致药剂师、患者和其他医疗专业人员对其接受程度较低且抵制实施。为了提高这类服务的接受程度并可能将其扩展到其他患者群体,在设计和实施过程中,不同医疗专业人员之间需要更多合作,还需要进行系统的数据收集以监测服务质量、对药剂师进行更好的培训,并为患者和医生提供更多信息。